Glycyrrhetinic acid exhibits strong inhibitory effects towards UDP-glucuronosyltransferase (UGT) 1A3 and 2B7

Phytotherapy Research

Volumn 27, Issue 9, 2013, Pages 1358-1361

  Huang, Yin Peng ^a   Cao, Yun Feng ^b   Fang, Zhong Ze ^b,c   Zhang, Yan Yan ^b   Hu, Cui Min ^c   Sun, Xiao Yu ^b   Yu, Zhen Wen ^b   Zhu, Xu ^b   Hong, Mo ^b   Yang, Lu ^b   Sun, Hong Zhi ^a,b  

^a JINZHOU MEDICAL UNIVERSITY   (China)

^b DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

glycyrrhetinic acid; glycyrrhizic acid; herb drug interaction; licorice; UDP glucuronosyltransferases (UGTs)

Indexed keywords

GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 2B7; GLYCYRRHETINIC ACID; ISOENZYME; LIVER ENZYME;

ARTICLE; CHEMICAL COMPOSITION; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEGLYCOSYLATION; DRUG INTERACTION; ENVIRONMENTAL FACTOR; ENZYME INHIBITION; ENZYME KINETICS; ENZYME SUBSTRATE; IN VITRO STUDY; INHIBITION KINETICS; NONCOMPETITIVE INHIBITION; PHARMACOKINETICS;

GLYCYRRHIZA;

GLYCYRRHETINIC ACID; GLYCYRRHIZIC ACID; HERB-DRUG INTERACTION; LICORICE; UDP-GLUCURONOSYLTRANSFERASES (UGTS);

GLUCURONOSYLTRANSFERASE; GLYCYRRHETINIC ACID; GLYCYRRHIZA; GLYCYRRHIZIC ACID; HERB-DRUG INTERACTIONS; HUMANS; ISOENZYMES; KINETICS; LIVER;

EID: 84883741370     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.4875     Document Type: Article

References (25)

1. Chintharlapalli S, Papineni S, Jutooru I, McAlees A, Safe S,. 2007. Structure-dependent activity of glycyrrhetinic acid derivatives as peroxisome proliferator-activated receptor {gamma} agonists in colon cancer cells. Mol Cancer Ther 6 (5): 1588-1598.
2. Cho SK, Oh ES, Park K, Park MS, Chung JY,. 2012. The UGT1A3*2 polymorphism affects atorvastatin lactonization and lipid-lowering effect in healthy volunteers. Pharmacogenet Genom 22: 598-605.
3. Court MH, Krishnaswamy S, Hao Q, et al,. 2003. Evaluation of 30-azido-30-deoxythymidine, morphine and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism. Drug Metab Dispos 31: 1125-1133.
4. Dong RH, Fang ZZ, Zhu LL, et al,. 2012. Investigation of UDP-glucuronosyltransferases (UGT) inhibitory properties of carvacrol. Phytother Res 26 (1): 86-90.
5. Fang ZZ, Zhang YY, Wang XL, Cao YF, Huo H, Yang L,. 2011. Bioactivation of Herbal Constituents: Simple Alerts in the complex system. Expert Opin Drug Met 7 (8): 989-1007.
6. Fiore C, Eisenhut M, Krausse R, et al,. 2007. Antiviral effects of Glycyrrhiza species. Phytother Res 22: 141-148.
7. Huang T, Fang ZZ, Yang L,. 2010. Strong inhibitory effect of medroxyprogesterone acetate (MPA) on UDP-Glucuronosyltransferase (UGT) 2B7 might induce drug-drug interactions (DDIs). Pharmazie 65 (12): 919-921.
8. Huang T, Fang ZZ, Zhang YY, et al,. 2011. Inhibitory potential of Chlormadinone acetate (CMA) on five important UDP-glucurosyltransferases in human liver. Pharmazie 66: 212-215.
9. Innocenti F, Iyer L, Ramirez J, Green MD, Ratain MJ,. 2001. Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7. Drug Metab Dispos 29: 686-692.
10. Iwai M, Maruo Y, Ito M, Yamamoto K, Sato H, Takeuchi Y,. 2004. Six novel UDP-glucuronosyltransferase (UGT1A3) polymorphisms with varying activity. J Hum Genet 49: 123-128.
11. Jing J, Ren W, Chen X, et al,. 2008. Glucuronide-sulfate diconjugate as a novel metabolite of glycyrrhetic acid in rat bile. Drug Metab Pharmacokinet 23: 175-180.
12. Kiang TKL, Ensom MHH, Chang TKH,. 2005. UDP-glucurosyltransferases and clinical drug-drug interactions. Pharmacol Ther 106: 97-132.
13. Knights KM, Bowalgaha K, Miners JO,. 2010. Spironolactone and canrenone inhibit UGT2B7-catalyzed human liver and kidney microsomal aldosterone 18beta-glucuronidation: a potential drug interaction. Drug Metab Dispos 38 (7): 1011-1014.
14. Liu Y, Zhang JW, Li W, et al,. 2006. Ginsenoside metabolites, rather than naturally occuring ginsenosides, lead to inhibition of human cytochrome P450 enzymes. Toxicol Sci 91 (2): 356-364.
15. Lu Y, Zhu J, Chen X, et al,. 2009. Identification of human UDP-glucuronosyltransferase isoforms responsible for the glucuronidation of glycyrrhetinic acid. Drug Metab Pharmacokinet 24 (6): 523-528.
16. Mackenzie PI, Bock KW, Burchell B, et al,. 2005. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics 15: 677-685.
17. Mano Y, Usui T, Kamimura H,. 2007. The UDP-glucuronosyltransferase 2B7 isozyme is responsible for gemfibrozil glucuronidation in the human liver. Drug Metab Dispos 35: 2040-2044.
18. Meza-Junco J, Chu QS, Christensen O, et al,. 2009. UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib. Cancer Chemother Pharmacol 65 (1): 1-4.
19. Miller AL,. 1998. Botanical influences on cardiovascular disease. Altern Med Rev 3 (6): 422-431.
20. Nakamura A, Nakajima M, Yamanaka H, Fujiwara R, Yokoi T,. 2008. Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines. Drug Metab Dispos 36: 1461-1464.
21. Parisella ML, Angelone T, Gattuso A, Cerra MC, Pellegrino D,. 2012. Glycyrrhizin and glycyrrhetinic acid directly modulate rat cardiac performance. J Nutr Biochem 23 (1): 69-75.
22. Radominska-Pandya A, Czernik PJ, Little JM, Battaglia E, Mackenzie PI,. 1999. Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev 31: 817-899.
23. Sharma G, Kar S, Palit S, Das PK,. 2012. 18β-glycyrrhetinic acid induces apoptosis through modulation of Akt/FOXO3a/Bim pathway in human breast cancer MCF-7 cells. J Cell Physiol 227 (5): 1923-1931.
24. Zhu LL, Ge GB, Liu Y, et al,. 2012. Potent and selective inhibition of magnolol on catalytic activities of UGT1A7 and 1A9. Xenobiotica. DOI: 10.3109/00498254.2012.681814
25. Zucker SD, Qin X, Rouster SD, et al,. 2001. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci USA 99 (22): 12671-12676